A Braf kinase-inactive mutant induces lung adenocarcinoma

Nature

Volumn 548, Issue 7666, 2017, Pages 239-243

  Nieto, Patricia ^a   Ambrogio, Chiara ^a,e   Esteban Burgos, Laura ^a   Gómez López, Gonzalo ^a   Blasco, María Teresa ^a   Yao, Zhan ^b   Marais, Richard ^c   Rosen, Neal ^b   Chiarle, Roberto ^d   Pisano, David G ^a   Barbacid, Mariano ^a   Santamaría, David ^a,f  

^a Structural Biology and Biocomputing Programme   (Spain)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MUTANT PROTEIN; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; RAS PROTEIN; BRAF PROTEIN, HUMAN; BRAF PROTEIN, MOUSE; KRAS PROTEIN, HUMAN; PROTEIN P21;

CANCER; CELLS AND CELL COMPONENTS; ENZYME ACTIVITY; GENE; INHIBITION; MUTATION; RODENT;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PREVENTION; CARCINOGENESIS; CELL TRANSDIFFERENTIATION; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MALE; NONHUMAN; ONCOGENE K RAS; ONCOLOGICAL PARAMETERS; PHENOTYPE; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN DEPLETION; TUMOR GROWTH; TUMOR VOLUME; ADENOCARCINOMA; ANIMAL; C57BL MOUSE; DISEASE EXACERBATION; GENETICS; LOSS OF FUNCTION MUTATION; LUNG TUMOR; MAPK SIGNALING; METABOLISM; MOUSE; PATHOLOGY; TUMOR SUPPRESSOR GENE;

MUS;

ADENOCARCINOMA; ALLELES; ANIMALS; CARCINOGENESIS; DISEASE PROGRESSION; FEMALE; GENES, NEUROFIBROMATOSIS 1; HUMANS; LOSS OF FUNCTION MUTATION; LUNG NEOPLASMS; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS P21(RAS);

EID: 85027336032     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature23297     Document Type: Article

References (31)

1. Chang, M. T. et al. Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat. Biotechnol. 34, 155-163 (2016).
2. Heidorn, S. J. et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209-221 (2010).
3. Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M. & Rosen, N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427-430 (2010).
4. Sebolt-Leopold, J. S. & Herrera, R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat. Rev. Cancer 4, 937-947 (2004).
5. Rauen, K. A. The RASopathies. Annu. Rev. Genomics Hum. Genet. 14, 355-369 (2013).
6. Hills, S. A. & Diffley, J. F. X. DNA replication and oncogene-induced replicative stress. Curr. Biol. 24, R435-R444 (2014).
7. Blasco, R. B. et al. c-Raf, but not Braf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. Cancer Cell 19, 652-663 (2011).
8. Kamata, T. et al. BRAF inactivation drives aneuploidy by deregulating CRAF. Cancer Res. 70, 8475-8486 (2010).
9. Guerra, C. et al. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell 4, 111-120 (2003).
10. Mainardi, S. et al. Identification of cancer initiating cells in K-Ras driven lung adenocarcinoma. Proc. Natl Acad. Sci. USA 111, 255-260 (2014).
11. Karreth, F. A., Frese, K. K., DeNicola, G. M., Baccarini, M. & Tuveson, D. A. C-Raf is required for the initiation of lung cancer by K-Ras(G12D). Cancer Discov. 1, 128-136 (2011).
12. Bartkova, J. et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434, 864-870 (2005).
13. Gorgoulis, V. G. et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434, 907-913 (2005).
14. Dietlein, F. et al. A synergistic interaction between Chk1-and MK2 inhibitors in KRAS-mutant cancer. Cell 162, 146-159 (2015).
15. Deschênes-Simard, X. et al. Tumor suppressor activity of the ERK/MAPK pathway by promoting selective protein degradation. Genes Dev. 27, 900-915 (2013).
16. Cheung, W. K. C. & Nguyen, D. X. Lineage factors and differentiation states in lung cancer progression. Oncogene 34, 5771-5780 (2015).
17. Andreadi, C. et al. The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/ MEK/ERK pathway. Genes Dev. 26, 1945-1958 (2012).
18. Langer, C. J., Besse, B., Gualberto, A., Brambilla, E. & Soria, J.-C. The evolving role of histology in the management of advanced non-small-cell lung cancer. J. Clin. Oncol. 28, 5311-5320 (2010).
19. Sutherland, K. D. et al. Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung. Cancer Cell 19, 754-764 (2011).
20. Xu, X. et al. Evidence for type II cells as cells of origin of K-Ras-induced distal lung adenocarcinoma. Proc. Natl Acad. Sci. USA 109, 4910-4915 (2012).
21. Sutherland, K. D. et al. Multiple cells-of-origin of mutant K-Ras-induced mouse lung adenocarcinoma. Proc. Natl Acad. Sci. USA 111, 4952-4957 (2014).
22. Buchert, M. et al. Genetic dissection of differential signaling threshold requirements for the Wnt/beta-catenin pathway in vivo. PLoS Genet. 6, e1000816 (2010).
23. Papa, A. et al. Cancer-associated PTEN mutants act in a dominantnegative manner to suppress PTEN protein function. Cell 157, 595-610 (2014).
24. Yao, Z. et al. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. Nature http://dx.doi.org/10.1038/nature23291 (2017).
25. Doma, E. et al. Skin tumorigenesis stimulated by Raf inhibitors relies upon Raf functions that are dependent and independent of ERK. Cancer Res. 73, 6926-6937 (2013).
26. Kammouni, W. et al. Increased K-ras protein and activity in mouse and human lung epithelial cells at confluence. Cell Growth Differ. 13, 441-448 (2002).
27. Carter, J. et al. Non-p.V600E BRAF mutations are common using a more sensitive and broad detection tool. Am. J. Clin. Pathol. 144, 620-628 (2015).
28. Chen, A. P. et al. Forebrain-specific knockout of B-raf kinase leads to deficits in hippocampal long-term potentiation, learning, and memory. J. Neurosci. Res. 83, 28-38 (2006).
29. Dankort, D. et al. A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev. 21, 379-384 (2007).
30. Jonkers, J. et al. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat. Genet. 29, 418-425 (2001).
31. Jackson, E. L. et al. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res. 65, 10280-10288 (2005).